These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 10745672)

  • 1. [Chronic inflammatory bowel disease--pathogenic concepts and therapeutic perspectives].
    Madsen JR
    Ugeskr Laeger; 2000 Mar; 162(10):1361-6. PubMed ID: 10745672
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An immunomodulation strategy targeted towards immunocompetent cells or cytokines in inflammatory bowel diseases (IBD).
    Heresbach D; Sémana G; Gosselin M; Bretagne MG
    Eur Cytokine Netw; 1999 Mar; 10(1):7-15. PubMed ID: 10210767
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy of inflammatory bowel diseases: current concepts and future perspectives.
    Neurath MF
    Arch Immunol Ther Exp (Warsz); 2000; 48(2):81-4. PubMed ID: 10807047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Immunology in medical practice. IV. Inflammatory bowel diseases: pathogenic starting points for specific therapy].
    van Deventer SJ
    Ned Tijdschr Geneeskd; 1997 Oct; 141(41):1956-9. PubMed ID: 9550744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Monitoring of bioavailability, pharmacokinetics and immunogenicity of tumour necrosis factor-alpha inhibitors].
    Steenholdt C; Ainsworth M; Thomsen OØ; Brynskov J; Bendtzen K
    Ugeskr Laeger; 2010 Jan; 172(1):44-7. PubMed ID: 20056095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytokine tumor necrosis factor-alpha A promoter gene polymorphism at position -308 G-->A and pediatric inflammatory bowel disease: implications in ulcerative colitis and Crohn's disease.
    Sýkora J; Subrt I; Dìdek P; Siala K; Schwarz J; Machalová V; Varvarovská J; Pazdiora P; Pozler O; Stozický F
    J Pediatr Gastroenterol Nutr; 2006 May; 42(5):479-87. PubMed ID: 16707968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Th17-cytokine blockers as a new approach for treating inflammatory bowel disease.
    Monteleone I; Pallone F; Monteleone G
    Ann Med; 2011 May; 43(3):172-8. PubMed ID: 21114459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent advances in biological therapy for inflammatory bowel disease.
    Kurtovic J; Segal I
    Trop Gastroenterol; 2004; 25(1):9-14. PubMed ID: 15303463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New cytokine therapeutics for inflammatory bowel disease.
    Stokkers PC; Hommes DW
    Cytokine; 2004 Nov 21-Dec 7; 28(4-5):167-73. PubMed ID: 15588691
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Introduction and overview: recent advances in the immunotherapy of inflammatory bowel disease.
    Hibi T; Inoue N; Ogata H; Naganuma M
    J Gastroenterol; 2003 Mar; 38 Suppl 15():36-42. PubMed ID: 12698869
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic inhibitors of tumor necrosis factor in Crohn's disease.
    Ganesan S; Travis SP; Ahmad T; Jazrawi R
    Curr Opin Investig Drugs; 2002 Sep; 3(9):1301-6. PubMed ID: 12498004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Review article: Infliximab therapy for inflammatory bowel disease--seven years on.
    Rutgeerts P; Van Assche G; Vermeire S
    Aliment Pharmacol Ther; 2006 Feb; 23(4):451-63. PubMed ID: 16441465
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms of action of infliximab in inflammatory bowel disease: an anti-inflammatory multitasker.
    Danese S
    Dig Liver Dis; 2008 Jul; 40 Suppl 2():S225-8. PubMed ID: 18598993
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Chronic inflammatory bowel disease - new therapies: tumor necrosis factor-antibodies and cytokines].
    Stange EF
    Z Gastroenterol; 2002 Apr; 40 Suppl 1():S90-S1. PubMed ID: 11930299
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Present states of development in new drugs and treatment of inflammatory bowel disease].
    Asakura H; Sugimura K
    Nihon Rinsho; 1999 Nov; 57(11):2490-5. PubMed ID: 10572418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumour necrosis factor and inflammatory bowel disease.
    Armstrong AM; Gardiner KR; Kirk SJ; Halliday MI; Rowlands BJ
    Br J Surg; 1997 Aug; 84(8):1051-8. PubMed ID: 9278640
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adacolumn for selective leukocytapheresis as a non-pharmacological treatment for patients with disorders of the immune system: an adjunct or an alternative to drug therapy?
    Saniabadi AR; Hanai H; Suzuki Y; Ohmori T; Sawada K; Yoshimura N; Saito Y; Takeda Y; Umemura K; Kondo K; Ikeda Y; Fukunaga K; Nakashima M; Beretta A; Bjarnason I; Lofberg R
    J Clin Apher; 2005 Oct; 20(3):171-84. PubMed ID: 15892107
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NF-kappaB in inflammatory bowel disease.
    Atreya I; Atreya R; Neurath MF
    J Intern Med; 2008 Jun; 263(6):591-6. PubMed ID: 18479258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of cytokine gene polymorphisms in determining disease susceptibility and phenotype in inflammatory bowel disease.
    Cantor MJ; Nickerson P; Bernstein CN
    Am J Gastroenterol; 2005 May; 100(5):1134-42. PubMed ID: 15842590
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Cytokine and anti-cytokine therapy in chronic inflammatory bowel diseases].
    Wittig BM; Zeitz M
    Dtsch Med Wochenschr; 2001 Jun; 126 Suppl 1():S52-8. PubMed ID: 11450615
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.